American Academy of Allergy, Asthma, and Immunology Virtual Annual Meeting (AAAAI 2022)

Treatment with benralizumab significantly reduces exacerbation rates in patients with asthma in a real-world setting, according to the ZEPHYR 2 study presented at AAAAI 2022.

Not only does tezepelumab reduce asthma symptomatic days, it prevents asthma exacerbations across all seasons in adolescents and adults with severe, uncontrolled asthma, according to the prespecified exploratory analyses of the NAVIGATOR trial presented at AAAAI 2022.

COVID-19 vaccination is generally well tolerated, even in people with mast cell activation syndrome (MCAS) —among whom vaccine hesitancy is high, according to studies presented at AAAAI 2022.

Treatment with intranasal budesonide significantly reduces nasal congestion symptoms in adults with rhinitis triggered or worsened by airborne pollution, according to a study presented at AAAAI 2022.

Real-world interim findings from the phase IV, noninterventional EMPOWER trial showed reduced attack rates and improved quality of life (QoL) in individuals who received lanadelumab for the treatment of hereditary angioedema (HAE).